Advanced Biomed Inc. (NASDAQ:ADVB) said it will carry out a 1-for-20 reverse stock split of its issued and outstanding common shares, effective at the opening of trading on The Nasdaq Stock Market on February 20, 2026.
The move follows written consent approval on January 12, 2026, by holders of a majority of the company’s voting power, in line with Section 78.320.2 of the Nevada Revised Statutes. Shareholders authorized a reverse split within a range of 1-for-2 to 1-for-100, leaving the final ratio and timing to the board’s discretion. On January 30, 2026, the board approved the 1-for-20 ratio.
The primary purpose of the consolidation is to restore compliance with Nasdaq Listing Rule 5550(a)(2), which requires companies listed on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share.
Beginning February 20, 2026, Advanced Biomed’s shares will trade on a split-adjusted basis under the existing ticker symbol “ADVB,” but with a new CUSIP number, 00752P203.
Under the terms of the reverse split, every 20 shares of common stock with a par value of US$0.001 will automatically convert into one share with the same par value. The action will apply uniformly to all shareholders and will not materially change any investor’s ownership percentage, except for minor adjustments related to fractional shares.
No fractional shares will be issued. Instead, shareholders entitled to a fractional share will receive one full share in its place. Investors holding shares through brokerage accounts are not required to take any action.
Following the consolidation, the number of issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536. The total number of authorized shares will remain unchanged.
More about Advanced Biomed Inc.
Advanced Biomed Inc., incorporated in Nevada, develops biomedical technologies focused on cancer detection and precision medicine. Through its Taiwan-based subsidiary, the company has built a proprietary microfluidics platform that combines semiconductor engineering with biotechnology to support circulating tumor cell (CTC) detection, enrichment and analysis.
Its product portfolio includes biochips and related devices designed for cancer screening, diagnostic applications, treatment selection and prognosis evaluation. The company is pursuing regulatory approvals in Taiwan and intends to expand into additional international markets.